BRISTOL MYERS SQUIBB COBMY
BRISTOL MYERS SQUIBB CO Financial Overview 2021–2025
Updated Jul 10, 2026Bristol Myers Squibb endured a brutal profitability swing, with earnings per share plunging to $-4.41 in FY2024 before rebounding to a positive $3.46 in FY2025. This stark recovery underscores a fundamental transition period as the biopharmaceutical giant aggressively manages the loss of exclusivity on established blockbuster drugs while funding its next generation of oncology and immunology therapies.
Despite heavy patent-cliff headwinds and continuous portfolio restructuring, baseline profitability has shown underlying resilience. Over the broader timeframe, earnings per share grew from $3.12 in FY2021 to $3.46 in FY2025. To support this pipeline transition and optimize its capital structure, the company executed a sweeping $7 billion cash tender offer in Q4 2025 to buy back outstanding notes. This massive debt restructuring was primarily funded by a new €5.00 billion public offering of senior unsecured notes, locking in interest rates between 2.973% and 4.581% across maturities stretching from 2030 to 2055.
The market's reaction to this portfolio overhaul and capital reallocation remains measured. At the close of FY2025, the stock traded at $53.94, commanding a price-to-earnings multiple of 15.6x. This valuation reflects a continuous balance between the successful integration of recent acquisitions and the ongoing pressure to replace aging revenue streams with newly launched therapeutic assets.
Recent Developments (Q4 2025 and Q1 2026)
During Q1 2026, Bristol Myers Squibb focused heavily on pipeline expansion and licensing agreements to offset impending patent cliffs. In early May 2026, shareholders elected all 11 director nominees to serve until the 2027 Annual Meeting and approved a new 2026 stock award and incentive plan, signaling strong confidence in the executive team. A shareholder proposal to establish an independent board chairperson was concurrently rejected.
Bulls argue the company's aggressive research and development investments will successfully yield next-generation blockbuster therapies. Bears counter that ongoing pricing constraints and fierce industry competition could severely limit the commercial success of these crucial assets. As of the April 30, 2026 reporting date, the stock traded at $60.59, carrying a valuation of 17.5x trailing earnings.
What to watch: clinical milestones for ongoing research programs; potential strategic acquisitions to bolster the broader therapeutic portfolio
Rev
$48.19B
FY2025
NI
$7.05B
FY2025
EPS$BMY
$3.47
FY2025
OCF
$14.16B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 8, 2026)
Bristol Myers Squibb Company (BMY) held its Annual Meeting of Shareholders on May 5, 2026, as detailed in this 8-K filing. The meeting saw decisive votes on key corporate governance and executive matters. All 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, shareholders provided advisory approval for the compensation of named executive officers and ratified the company's 2026 stock award and incentive plan, signaling support for the company's incentive structures. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received overwhelming ratification. However, a shareholder proposal advocating for an independent board chairperson was not approved, suggesting that the current governance structure, where the roles may be combined or held by a non-independent director, remains favored by the majority of shareholders at this time. Overall, the results reflect robust shareholder support for BMY's management, operational plans, and existing governance framework.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 30, 2026)
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on April 30, 2026, to report its financial results for the first quarter of 2026. The filing includes a press release detailing these results and a presentation on financial and operating initiatives, both of which are available on the company's website. Investors should note that the company is referencing non-GAAP financial information and provides reconciliations to GAAP measures within the furnished materials. This report serves as an announcement of the company's quarterly performance and strategic outlook. While specific financial figures are not detailed within the 8-K text itself, the furnished exhibits (Exhibit 99.1 and 99.2) are the primary sources for understanding BMY's performance and forward-looking statements for the first quarter of 2026. Investors are encouraged to review these exhibits for comprehensive details on revenue, profitability, and any strategic updates shared during the associated conference call.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 5, 2026)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 5, 2026, to announce its financial results for the fourth quarter and full year of 2025. The filing includes a press release (Exhibit 99.1) detailing these results and a presentation (Exhibit 99.2) covering financial and operating initiatives. Investors should refer to these documents, available on the company's website, for a comprehensive understanding of BMY's recent performance and strategic direction. Both the press release and presentation reference non-GAAP financial information. The company emphasizes that reconciliations between non-GAAP and GAAP measures, along with explanations for the use of non-GAAP figures, are provided within the press release. Investors are advised to review these reconciliations carefully when evaluating the company's financial health and operational efficiency.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on January 12, 2026, to disclose an investor presentation made available on their website on January 11, 2026. This presentation, attached as Exhibit 99.1, is intended to provide updates and insights to investors regarding the company's strategic direction, performance, and future outlook. While the filing itself does not contain new financial results or material events beyond the presentation, it serves as a crucial communication channel for investors seeking the latest information directly from the company. Investors are encouraged to review the presentation for details on BMY's ongoing initiatives, pipeline updates, and market positioning, as this is the primary vehicle through which the company is sharing this information in connection with this filing.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 18, 2025)
Bristol Myers Squibb Company (BMY) has filed an 8-K report detailing the results of its previously announced cash tender offers for its outstanding notes. The company announced early participation results on November 17, 2025, and on November 18, 2025, it released the accepted amounts and pricing terms of these offers. These tender offers are part of a strategy to manage its debt obligations, with full details provided in the Offer to Purchase document dated November 3, 2025. Investors should note that this filing primarily concerns debt management and does not represent an offer to buy or sell equity securities. The early participation results and final pricing indicate the company's progress in its debt restructuring efforts, which could impact its financial leverage and interest expense going forward. The full financial implications will be clearer as the settlement process concludes and is reflected in future financial statements.
View all 8-K filings →